Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Clearmind Medicine Files Three Provisional Patent Applications With USPTO

The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc's Cannamide™ and classical psychedelics
byBill Haddad
February 15, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s Cannamide™ and classical psychedelics

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts